Brand NamesWithin the states
AlertBoxed warnings
Hypersensitivity reactions
Exacerbations of hepatitis B
AdministrationOral
With or without food
With or without food
ADRTop 10%
Mostly Central (CNS) and Gastrointestinal
Mostly Central (CNS) and Dermatologic
Contraindications Avoid
Hypersensitivity, patients who are positive for the HLA-B*5701 allele and moderate to severe hepatic impairment
Hypersensitivity
DosingAdult
300 mg twice daily or 600 mg once daily
[HIV-1 infection]
150 mg twice daily or 300 mg once daily
[Hepatitis B]
100 mg once daily
[Hepatitis B/HIV coinfection]
150 mg twice daily or 300 mg once daily
Excretion
Urine
Urine, majority as unchanged drug
Half-Life Elimination
12 to 26 hours
10 to 15 hours
MOAMechanism of action
Inhibition of viral replication
Inhibition of HIV reverse transcription.
Incorporated into the viral DNA by hepatitis B virus polymerase, resulting in DNA chain termination
Pregnancy
Use cautiously
Use cautiously
Breast-FeedingLactation
Not recommended
Not recommended
General precautions for both abacavir and lamivudine
- Consumption of alcoholic beverages may increase the plasma concentrations an pharmacologic effects of Abacavir.
- No Drug-Food Interactions information found for Abacavir or lamivudine.
- Patient may be at increased risk for lactic acidosis, severe hepatomegaly with steatosis, and/or hepatic failure.